Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-201 (Semaglutide Microneedle Patch) vs Subcutaneous Semaglutide in Healthy Overweight and Obese Participants
NCT07673900Phase 1Recruiting
- Sponsor
- Terrestrial Bio
- Start
- Jun 2026
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 1, randomised trial of semaglutide in obesity and Overweight (6 arms), sponsored by Terrestrial Bio. Primary endpoint: Treatment Emergent Adverse Events at 5 weeks. Started Jun 2026; status: recruiting.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT07673900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07673900.